HIV vector production mediated by Rev protein transduction

Molecular Therapy

Volumn 8, Issue 2, 2003, Pages 324-331

  Kowolik, Claudia M ^a   Yam, Priscilla ^a   Yu, Ying ^a   Yee, Jiing Kuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; PLASMID VECTOR; RECOMBINANT PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CELL LINE; CELL TRANSPORT; CONTROLLED STUDY; GENE CONSTRUCT; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DOMAIN; PROTEIN PURIFICATION; STANDARDIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS TITRATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0041854295     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00166-7     Document Type: Article

References (41)

1. Naldini, L, et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
2. Bukrinsky, M. I., et al. (1993). A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365: 666-669.
3. Kafri, T., et al. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
4. Case, S. S., et al. (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96: 2988-2993.
5. Amado, R. G., and Chen, I. S. (1999). Lentiviral vectors - The promise of gene therapy within reach? Science 285: 674-676.
6. Buchschacher, G. L. Jr., and Wong-Staal, F. (2000). Development of lentiviral vectors for gene therapy for human diseases. Blood 95: 2499-2504.
7. Kafri, T. (2001). Lentivirus vectors: difficulties and hopes before clinical trials. Curr. Opin. Mol. Ther. 3: 316-326.
8. Gasmi, M., et al. (1999). Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J. Virol. 73: 1828-1834.
9. Pandya, S., et al. (2001). Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum. Gene Ther. 12: 847-857.
10. Wagner, R., et al. (2000). Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum. Gene Ther. 11: 2403-2413.
11. Zufferey, R., et al. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.
12. Kim, V. N., et al. (1998). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72: 811-816.
13. Zufferey, R., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72: 9873-9880.
14. Miyoshi, H., et al. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
15. Dull, T., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
16. Malim, M. H., et al. (1989). The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338: 254-257.
17. Cochrane, A. W., Chen, C. H., and Rosen, C. A. (1990). Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc. Natl. Acad. Sci. USA 87: 1198-1202.
18. Emerman, M., Vazeux, R., and Peden, K. (1989). The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell 57: 1155-1165.
19. Schneider, R., et al. (1997). Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71: 4892-4903.
20. Maldarelli, F., Martin, M. A., and Strebel, K. (1991). Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J. Virol. 65: 5732-5743.
21. Kotsopoulou, E., et al. (2000). A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74: 4839-4852.
22. Schwarze, S. R., et al. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
23. Elliott, G., and O'Hare, P. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88: 223-233.
24. Vocero-Akbani, A., Lissy, N. A., and Dowdy, S. F. (2000). Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol. 322: 508-521.
25. Han, K., et al. (2001). Efficient intracellular delivery of an exogenous protein GFP with genetically fused basic oligopeptides. Mol. Cells 12: 267-271.
26. Matsushita, M., et al. (2001). A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J. Neurosci. 21: 6000-6007.
27. Peitz, M., et al. (2002). Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc. Natl. Acad. Sci. USA 99: 4489-4494.
28. Xia, H., Mao, Q., and Davidson, B. L. (2001). The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19: 640-644.
29. Derossi, D., et al. (1996). Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271: 18188-18193.
30. Morris, M. C., et al. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19: 1173-1176.
31. Futaki, S., et al. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276: 5836-5840.
32. Henklein, P., et al. (2000). Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J. Biol. Chem. 275: 32016-32026.
33. Kowolik, C. M., and Yee, J. K. (2002). Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus f protein. Mol. Ther. 5: 762-769.
34. Yee, J. K., et al. (1994). Requirements for efficient production of human immunodeficiency virus type 1-based vectors. J. Virol. 73: 1828-1834.
35. Yam, P. Y., et al. (2002). Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol. Ther. 5: 479-484.
36. Nagahara, H., et al. (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4: 1449-1452.
37. Gao, G. P., et al. (2002). Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 5: 644-649.
38. Qiao, C., et al. (2002). A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 76: 13015-13027.
39. Okada, T., et al. (2001). Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated virus vector production. Biochem. Biophys. Res. Commun. 288: 62-68.
40. Satoh, W., et al. (2000). Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on Cre-loxP recombination. J. Virol. 74: 10631-10638.
41. Graham, F.L., and van der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467.